I agree that 'breakthrough' is a premature description if the reader thinks that it applies to pre-clinical drugs targeting pancreatic and gallbladder cancers.
I respectfully suggest, however, that the breakthrough in this case refers to the ability to retard the Phase 2 metabolism process.
I agree that 'breakthrough' is a premature description if the...
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
-0.010(8.70%) |
Mkt cap ! $30.68M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.0¢ | 9.5¢ | $44.55K | 439.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14461 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 8665 | 2 |
View Market Depth
| Last trade - 15.39pm 10/10/2024 (20 minute delay) ? |
| NOX (ASX) Chart |